Lithera beta agonist begins trial as fat-buster

03/19/2013 | Xconomy

Lithera announced the launch of a 500-patient, Phase II trial of an injectable version of salmeterol xinafoate for localized reduction of abdominal fat tissue. The selective beta agonist is approved in aerosol form as an inhaled asthma treatment.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA